Yumanity’s approach to neurodegenerative diseases validated by two external collaborations

Yumanity Achieves Research Milestone in Collaboration with Merck; Yumanity to receive $ 5 million milestone payment

Michael J. Fox Foundation grants grant to accelerate first proof-of-concept testing of promising treatment for Parkinson’s disease

BOSTON, Jan. 11, 2022 (GLOBE NEWSWIRE) – Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative disease-modifying therapies for neurodegenerative diseases, today made the update on the evolutions of the company. This includes completing a research milestone for our Amyotrophic Lateral Sclerosis (ALS) / Frontotemporal Lobar Dementia (FTLD) Joint Program, which triggered a $ 5 million milestone payment to Merck’s Yumanity and award. a research grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to accelerate the first proof of concept testing of a promising treatment for Parkinson’s disease.

“The development of effective treatments for neurodegenerative diseases has been difficult in the past, due to a lack of in-depth understanding of the pathophysiological processes underlying these diseases,” said Paulash Mohsen, Commercial Director of Yumanity. “Our target discovery engine is designed to reveal these processes and identify targets for therapeutic intervention. We are very excited to further validate the strength of our platform through our collaborations with Merck and the Michael J. Fox Foundation and look forward to their future progress.

Update of the Merck-Yumanity collaboration agreement

As part of the collaboration agreement announced in June 2020, Merck has secured the exclusive rights to two new Yumanity programs for the treatment of ALS and FTLD. Yumanity and Merck are collaborating to advance both preclinical programs during the research period, after which Merck has the right to continue efforts in preclinical discovery, clinical development and commercialization. Yumanity has received an upfront payment and is eligible to receive research, development and sales milestone payments of up to $ 525 million associated with the successful development of marketed products for the pipeline programs, as well as royalties on net sales.

MJFF scholarship

Yumanity received a $ 500,000 grant to further investigate preclinical efficacy and biomarker development for YTX-7739, which is under clinical development for the treatment of Parkinson’s disease. YTX-7739 is Yumanity Therapeutics’ proprietary investigational small molecule therapy designed to penetrate the blood brain barrier and inhibit the activity of a novel target, stearoyl-CoA desaturase. Yumanity recently announced the first results of its successful Phase 1b clinical trial for YTX-7739 in patients with Parkinson’s disease and plans to begin its Phase 2 randomized clinical trial in 2022.

“MJFF is a globally recognized advocate and supporter of innovative research into new treatments to stop Parkinson’s disease and relieve symptoms,” said Dan Tardiff, vice president of translational research at Yumanity and principal investigator of the grant . “We are proud to be recognized by the award of this grant as a contributor to the urgent search for a cure for Parkinson’s disease. “

About Yumanity Therapeutics
Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its science base and drug discovery platform. The Company’s most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson’s disease. Yumanity’s drug discovery platform enables the Company to rapidly screen for disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurogenerative diseases. Yumanity’s pipeline includes additional programs focused on Lewy Body Dementia, Multisystem Atrophy, Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s Disease), Frontotemporal Lobar Dementia (FTLD), and Alzheimer’s Disease. For more information, please visit www.yumanity.com.

Forward-looking statements
This press release contains forward-looking statements, including statements made in accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by words and phrases such as “objectives”, “anticipate “,” Believe, “could”, “designed for”, “estimate”, “expect”, “forecast”, “objective”, “intention”, “may”, “plan”, “possible” , “Potential”, “research”, “will” and variations of such words and expressions or similar expressions which are intended to identify forward-looking statements. These forward-looking statements include, without limitation, statements regarding the potential therapeutic benefits of our potential product candidates and the results of preclinical studies, including YTX-7739, and the design, initiation, recruitment and timing of trials. ongoing or planned clinics, trial results, product approvals and regulatory pathways, and expected benefits from our drug discovery platform. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Results from preclinical or early-stage clinical trials may not be indicative of results from later-stage or larger-scale clinical trials and do not guarantee regulatory approval. You should not place undue reliance on these statements or the scientific data presented.

All forward-looking statements contained in this press release are based on Yumanity Therapeutics’ current expectations, estimates and projections regarding our industry as well as the current beliefs and expectations of management regarding future events only as of today and are subject to a number of risks and uncertainties which could cause actual results to differ materially and adversely from those stated or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that one or more of our product candidates will not be successfully developed or marketed, the risk of discontinuation or delay of any ongoing or planned clinical trials of Yumanity. Therapeutics or our collaborators. , the risk that Yumanity Therapeutics will not successfully recruit or enroll a sufficient number of patients for our clinical trials, the risk that Yumanity Therapeutics will not realize the expected benefits of its drug discovery platform, the risk that our product candidates will not ‘do not have the safety or efficacy profile that we anticipate, the risk that previous results, such as signals of safety, activity or durability of the effect, observed in preclinical or clinical trials, may not may not be reproduced or continue in ongoing or future studies or trials involving Yumanity Therapeutics’ product candidates, the risk that we may not be able to obtain and maintain regulatory approval for our product may date, risk that the size and growth potential of the market for our product candidates will not materialize as expected, the risks associated with our dependence on a supplier rs and third party manufacturers, risks relating to the accuracy of our estimates of future expenses and income, risks relating to our capital and additional funding requirements, risks relating to clinical trials and business disruptions resulting from the COVID-19 epidemic or similar public health crises, including the fact that such interruptions may significantly delay our enrollment and development schedules and / or increase our development costs or collection efforts. data may be compromised or otherwise affected by such crises, and risks relating to our ability to obtain and maintain intellectual property protection for our product candidates. For a discussion of these risks and uncertainties, as well as other important factors, each of which could cause Yumanity Therapeutics’ actual results to differ materially and adversely from those contained in forward-looking statements, see the section entitled ” risk ”in Yumanity Therapeutics most recent annual or quarterly report and other material factors in Yumanity Therapeutics’ subsequent filings with the Securities and Exchange Commission. Yumanity Therapeutics expressly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

Burns McClellan, Inc.
Lee roth
[email protected]
(212) 213-0006

Burns McClellan, Inc.
Robert Flamm, Ph.D.
[email protected]
(212) 213-0006

Shirlene J. Manley